Phase 1 · NCT05916560
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Hepatic Impairment Compared With Healthy Participants
CompletedVerified
Trial registry record
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- A Study of LY3437943 in Participants With Impaired and Normal Liver Function
- ClinicalTrials.gov ID
- NCT05916560
- Indication
- Healthy, Hepatic Insufficiency
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 43
- Status
- Completed
- Interventions
- Drug: LY3437943
- Comparator
- Not reported
- Eligible ages
- 18 Years – 85 Years
- Locations
- 5 sites · United States
- Study start
- 13 Jul 2023
- Primary completion
- 2 Mar 2025
- Study completion
- 2 Mar 2025
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 18 Apr 2025
Endpoints
Primary
Pharmacokinetics (PK): Area under the concentration versus time curve from time zero to infinity (AUC0-∞) of LY3437943; PK: Maximum observed concentration (Cmax) of LY3437943